Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma
NCT00361088 · H. Lee Moffitt Cancer Center and Research Institute · PHASE1/PHASE2 · terminated · last registry update 2013-11-25 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Initial Principal Investigator left Moffitt” | Open Targets' class: study staff moved | Registry record, H. Lee Moffitt Cancer Center and Research Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PSMD1 in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2014-11-20Results posted on the registry: University of Michigan Rogel Cancer Center, carfilzomib, lenalidomide plus dexamethasone + carfilzomib, lenalidomide plus dexamethasone (NCT01029054)
- 2014-07-04Phase 3 first posted: Takeda, Ixazomib Citrate + Placebo (NCT02181413)
- 2013-12-09Results posted on the registry: Amgen, carfilzomib + carfilzomib (NCT00511238)
- 2013-05-29Phase 3 first posted: ECOG-ACRIN Cancer Research Group, Bortezomib + Carfilzomib (NCT01863550)
- 2013-05-09Phase 3 first posted: Millennium Pharmaceuticals, Inc., Ixazomib + Placebo (NCT01850524)
- 2013-03-26Phase 3 first posted: Amgen, Carfilzomib + Bortezomib (NCT01818752)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision